References in periodicals archive

The company said the US FDA has approved the additional indication for ALIMTA (pemetrexed for injection) plus carboplatin and KEYTRUDA (pembrolizumab) for initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

Eli Lilly and Company passes US FDA approval for new indication for ALIMTA, carboplatin and KEYTRUDA combination for NSCLC

IMpower133 is a Phase III, multicenter, double-blinded, randomized placebo- controlled study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin and etoposide) alone in chemotherapy-naive people with ES-SCLC.

FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer

The overall response rate for the carboplatin regimen was 75.9%, with 36.1% complete responses.

Regimen Promises Less Severe Neurotoxicity With Chemotherapy

Placebo and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for four cycles and paclitaxel 200 mg/m2 on Day 1 of each 21-day cycle for four cycles or nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 21-day cycle for four cycles, followed by placebo every 3 weeks.

European Commission Approves US Merck's Keytruda (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer

The study, supported by the US National Cancer Institute (NCI), will evaluate the efficacy and safety of the combination of belinostat and carboplatin, or BelCar, in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or peritoneal cancer.

TopoTarget says belinostat enters phase II trial in USA

Sandra Horning, MD, Roche's chief medical officer and head of Global Product Development, said: "Our phase III results showed TECENTRIQ in combination with Avastin, paclitaxel and carboplatin has the potential to provide a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer.

Roche's cancer immunotherapy TECENTRIQ (atezolizumab) granted FDA priority review for initial treatment of specific type of metastatic lung cancer

Eli Lilly (LLY) announced that the FDA has granted approval for a new indication for Alimta in combination with carboplatin and Keytruda for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, or NSCLC, irrespective of PD-L1 expression status.

Eli Lilly announces Alimta label expanded by FDA

Switzerland-based Roche has indicated a clinically significant survival benefit in a phase III lung cancer study of its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy), it was reported on Monday.

Roche's phase III lung cancer study of Tecentriq combined with Avastin indicates clinically significant survival benefit

M2 PHARMA-November 2, 2018-FDA Approves US Merck's Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

FDA Approves US Merck's Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)